By combining advanced AI and biomedical data, Knowing01 is transforming research on complex data sets. For four years, the team has been developing software for analyzing biomedical markers in the context of large data sets. The AI-powered platform helps pharmaceutical and BiotechCompanies and researchers to make better decisions in disease research and drug development. According to founder Nikola Müller, this will make 80 to 95 percent of previously unused biomedical data accessible. The user-friendly solution is intended to reduce costs and risks in drug development.
The concept has now also convinced investors, who are providing the startup with a six-figure sum. In addition to Backbone Ventures, various business angels from the DACH region, including Julia Ju, Veronika Chrestin, Björn Schäfer, and Johannes Stiber, also invested. The funding will enable Knowing01 to accelerate the development of its software for contextualizing molecular data and expand its team.
Last year, the company was able to launch its first product to the European biotech market. The proprietary AI-powered multiomics platform enables researchers to gain insights from existing data using a scalable in silico approach. This is intended to achieve better research results while reducing error rates. Multiomics integrates various biological data types such as genomics, proteomics, and transcriptomics, creating a comprehensive overview of biological processes.
Nikola Müller, founder and CEO of Knowing01, explains:
“With our solution, we enable scientists to leverage untapped data sources and make more informed decisions in drug development.”
